DXT.TO vs. AZN
DXT.TO (Dexterra Group Inc.) and AZN (AstraZeneca PLC) are both stocks. DXT.TO operates in Specialty Business Services (Industrials), while AZN operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, DXT.TO returned 7.72%/yr vs 17.04%/yr for AZN. At a 0.08 correlation, their price movements are largely independent.
Performance
DXT.TO vs. AZN - Performance Comparison
Loading charts...
Different Trading Currencies
DXT.TO is traded in CAD, while AZN is traded in USD. To make them comparable, the AZN values have been converted to CAD using the latest available exchange rates.
Returns By Period
In the year-to-date period, DXT.TO achieves a 12.80% return, which is significantly higher than AZN's 3.75% return. Over the past 10 years, DXT.TO has underperformed AZN with an annualized return of 7.72%, while AZN has yielded a comparatively higher 17.04% annualized return.
DXT.TO
- 1D
- 1.48%
- 1M
- 3.66%
- YTD
- 12.80%
- 6M
- 10.53%
- 1Y
- 51.53%
- 3Y*
- 39.21%
- 5Y*
- 22.12%
- 10Y*
- 7.72%
AZN
- 1D
- 1.07%
- 1M
- 2.44%
- YTD
- 3.75%
- 6M
- 5.00%
- 1Y
- 31.58%
- 3Y*
- 11.50%
- 5Y*
- 15.03%
- 10Y*
- 17.04%
DXT.TO vs. AZN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
DXT.TO Dexterra Group Inc. | 12.80% | 55.32% | 43.20% | 11.05% | -31.72% | 38.36% | 8.40% | -30.88% | 17.73% | -20.59% |
AZN AstraZeneca PLC | 3.75% | 36.76% | 7.80% | -0.97% | 26.69% | 19.60% | 0.67% | 30.09% | 23.44% | 24.09% |
Correlation
The correlation between DXT.TO and AZN is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.13 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.10 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.09 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.08 |
Correlation (All Time) Calculated using the full available price history since Jul 26, 2006 | 0.08 |
Fundamentals
DXT.TO:
CA$829.70M
AZN:
$286.33B
DXT.TO:
CA$0.72
AZN:
$6.66
DXT.TO:
18.08
AZN:
27.56
DXT.TO:
0.11
AZN:
0.04
DXT.TO:
0.76
AZN:
4.74
DXT.TO:
2.85
AZN:
6.05
DXT.TO:
CA$1.08B
AZN:
$60.44B
DXT.TO:
CA$161.12M
AZN:
$49.37B
DXT.TO:
CA$113.74M
AZN:
$20.47B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
DXT.TO vs. AZN — Risk / Return Rank
DXT.TO
AZN
DXT.TO vs. AZN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Dexterra Group Inc. (DXT.TO) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| DXT.TO | AZN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.83 | ||
| Sortino ratioReturn per unit of downside risk | +0.81 | ||
| Omega ratioGain probability vs. loss probability | 1.37 | 1.23 | +0.14 |
| Calmar ratioReturn relative to maximum drawdown | 3.74 | 2.21 | +1.53 |
| Martin ratioReturn relative to average drawdown | 9.01 | 5.50 | +3.50 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| DXT.TO | AZN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.06 | 1.23 | +0.83 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.80 | 0.61 | +0.19 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.18 | 0.66 | -0.49 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.01 | 0.43 | -0.42 |
Drawdowns
DXT.TO vs. AZN - Drawdown Comparison
The maximum DXT.TO drawdown since its inception was -97.14%, which is greater than AZN's maximum drawdown of -49.50%. Use the drawdown chart below to compare losses from any high point for DXT.TO and AZN.
Loading charts...
Drawdown Indicators
| DXT.TO | AZN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.14% | -49.50% | -47.64% |
Max Drawdown (1Y)Largest decline over 1 year | -13.84% | -14.39% | +0.55% |
Max Drawdown (3Y)Largest decline over 3 years | -13.91% | -25.38% | +11.47% |
Max Drawdown (5Y)Largest decline over 5 years | -44.49% | -25.38% | -19.11% |
Max Drawdown (10Y)Largest decline over 10 years | -91.68% | -26.18% | -65.50% |
Current DrawdownCurrent decline from peak | -62.28% | -10.24% | -52.04% |
Average DrawdownAverage peak-to-trough decline | -59.33% | -13.30% | -46.03% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.74% | 5.77% | -0.03% |
Volatility
DXT.TO vs. AZN - Volatility Comparison
The current volatility for Dexterra Group Inc. (DXT.TO) is 5.90%, while AstraZeneca PLC (AZN) has a volatility of 7.48%. This indicates that DXT.TO experiences smaller price fluctuations and is considered to be less risky than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| DXT.TO | AZN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.90% | 7.48% | -1.58% |
Volatility (6M)Calculated over the trailing 6-month period | 18.82% | 17.93% | +0.89% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.18% | 25.95% | -0.77% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 27.74% | 24.83% | +2.91% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 43.84% | 25.75% | +18.09% |
Dividends
DXT.TO vs. AZN - Dividend Comparison
DXT.TO's dividend yield for the trailing twelve months is around 2.98%, more than AZN's 2.90% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AZN AstraZeneca PLC | 2.90% | 1.70% | 2.27% | 2.15% | 2.12% | 2.35% | 2.80% | 2.81% | 3.69% | 3.95% | 5.01% | 4.06% |
DXT.TO Dexterra Group Inc. | 2.98% | 3.22% | 4.49% | 6.08% | 6.35% | 3.78% | 2.31% | 1.30% | 0.89% | 1.04% | 0.82% | 2.48% |
Financials
DXT.TO vs. AZN - Financials Comparison
This section allows you to compare key financial metrics between Dexterra Group Inc. and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
DXT.TO vs. AZN - Profitability Comparison
DXT.TO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Dexterra Group Inc. reported a gross profit of 38.52M and revenue of 275.47M. Therefore, the gross margin over that period was 14.0%.
AZN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.
DXT.TO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Dexterra Group Inc. reported an operating income of 15.71M and revenue of 275.47M, resulting in an operating margin of 5.7%.
AZN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.
DXT.TO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Dexterra Group Inc. reported a net income of 13.52M and revenue of 275.47M, resulting in a net margin of 4.9%.
AZN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.
Frequently Asked Questions
DXT.TO and AZN have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for DXT.TO and AZN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer